Maraviroc (Selzentry, Celsentri)

Overview | Research & News

Overview

Selzentry (Maraviroc, Celsentri) Official Prescribing Information and Drug Warnings (PDF) (November 2011)
From ViiV Healthcare
FDA Approves First CCR5 Inhibitor Maraviroc (August 7, 2007)
The U.S. Food and Drug Administration (FDA) approved Pfizer's maraviroc (Selzentry), which belongs to a new class of antiretrovirals that could provide an alternative for patients who have developed multidrug resistance.
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Approval of Maraviroc (August 6, 2007)
From U.S. Food and Drug Administration
Maraviroc Overview: An Interview With Joel Gallant, M.D., M.P.H. (August 6, 2007)
From TheBodyPRO.com

MOST VIEWED ARTICLES

	HIV Management Today: Mental Health & HIV, the Uncharted Territory
	Danish Study Targets HIV Reservoir, in Latest Search for HIV Cure
	10 Top Studies Whose Impact Will Last Well Beyond CROI 2013
	CROI 2013: Women's Issues in HIV Research (Video)
	PrEP Failures and Successes: One Study Whose Impact Will Last Well Beyond CROI 2013
	HIV Opportunistic Infection Guidelines Updated

More Most Viewed Articles

TheBodyPRO.com is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. TheBodyPRO.com and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO.com's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.